USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2

Background: The most commonly preferred chemotherapeutic agents to treat cancers are small-molecule drugs. However, the differential sensitivity of various cancer cells to small molecules and untargeted delivery narrow the range of potential therapeutic applications. The mechanisms responsible for d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Arun Pandian, Kaushal, Kamini, Park, Chang-Hwan, Kim, Kye-Seong, Ramakrishna, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581437/
https://www.ncbi.nlm.nih.gov/pubmed/34815782
http://dx.doi.org/10.7150/thno.63806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581437/
https://www.ncbi.nlm.nih.gov/pubmed/34815782
http://dx.doi.org/10.7150/thno.63806

Ejemplares similares